Medicine Grand Rounds – Integrating Omics into Medicine: Where we are and where we should be

When:
August 6, 2014 @ 8:00 am – 9:00 am
2014-08-06T08:00:00-07:00
2014-08-06T09:00:00-07:00
Where:
Li Ka Shing Center for Learning and Knowledge, Berg Hall
300 Pasteur Drive
Stanford University, Stanford, CA 94304
USA
Cost:
Free
Contact:
Department of Medicine
650-721-1166
Medicine Grand Rounds - Integrating Omics into Medicine: Where we are and where we should be @ Li Ka Shing Center for Learning and Knowledge, Berg Hall | Stanford | California | United States

Presenter: Michael Snyder, PhD
Professor and Chair of Genetics
Director, Stanford Center for Genomics and Personalized Medicine

Michael Snyder is the Stanford Ascherman Professor and Chair of Genetics and the Director of the Center of Genomics and Personalized Medicine. Dr. Snyder received his Ph.D. training at the California Institute of Technology and carried out postdoctoral training at Stanford University. He is a leader in the field of functional genomics and proteomics, and one of the major participants of the ENCODE project. His laboratory study was the first to perform a large-scale functional genomics project in any organism, and has launched many technologies in genomics and proteomics. These including the development of proteome chips, high resolution tiling arrays for the entire human genome, methods for global mapping of transcription factor binding sites (ChIP-chip now replaced by ChIP-seq), paired end sequencing for mapping of structural variation in eukaryotes, de novo genome sequencing of genomes using high throughput technologies and RNA-Seq. These technologies have been used for characterizing genomes, proteomes and regulatory networks. Seminal findings from the Snyder laboratory include the discovery that much more of the human genome is transcribed and contains regulatory information than was previously appreciated, and a high diversity of transcription factor binding occurs both between and within species. He has also combined different state-of–the-art “omics” technologies to perform the first longitudinal detailed integrative personal omics profile (iPOP) of person and used this to assess disease risk and monitor disease states for personalized medicine. He is a cofounder of several biotechnology companies, including Protometrix (now part of Life Tehcnologies), Affomix (now part of Illumina), Excelix, and Personalis, and he presently serves on the board of a number of companies.